https://orcid.org/0000-0002-4253-0662
Figures & data
Table 1. Demographics and baseline clinical characteristics of the SABINA III African population by investigator-classified asthma severity and practice type.
Table 2. Asthma characteristics of the SABINA III African population according to investigator-classified asthma severity and practice type.
Figure 1. Proportion of patients (%) receiving SABA prescriptions in the 12 months before the study visit according to investigator-classified asthma severity and practice type in the SABINA III African cohort (N = 1778): (A) all patients, (B) mild asthma, and (C) moderate-to-severe asthma. *Patients without SABA prescriptions did not report which reliever they were using. Abbreviations. SABA, short-acting β2-agonist; SABINA, SABA use IN asthma.
Table 3. Asthma treatments prescribed and SABA canisters purchased OTC in the 12 months before the study visit by patients in the SABINA III African cohort.
Figure 2. Association of SABA prescriptions with (A) severe exacerbations in the 12 months before the study visit and (B) level of asthma control assessed during the study visit in the SABINA III African cohort. Abbreviations. BMI, body mass index; CI, confidence interval; GINA, global initiative for asthma; IRR, incidence rate ratio; OR, odds ratio; SABA, short-acting β2-agonist; SABINA, SABA use IN asthma. Based on the covariable significance in the models, IRRs are corrected by country, age, sex, BMI, tobacco smoking history, GINA step, healthcare insurance, prescriber type, comorbidity, asthma duration, and education level. ORs are corrected by country, age, sex, BMI, asthma duration, tobacco smoking history, comorbidity, GINA step, healthcare insurance, prescriber type, and education level.
Supplemental_Material_CLEAN.docx
Download MS Word (562.4 KB)Data availability statement
Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.